



Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: DVAX

| | |
|---------------|----------------------------|
| Last Trade: | 17.88 |
| Trade Time: | 9:57 AM ET Feb 20, 2018 |
| Change: | 0.65 (+3.774%) |
| Day Range | 17.50 - 18.50 |
| 52-Week Range | 3.90 - 24.45 |
| Volume | 284,546 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Feb 20, 2018*
[Dynavax Secures \\$175 Million in Non-Dilutive Debt Financing](#)
- Feb 14, 2018*
[Dynavax to Present at the RBC Capital Markets Global Healthcare Conference](#)
- Feb 2, 2018*
[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Jan 12, 2018*
[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Jan 8, 2018*
[Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults](#)

Upcoming Events [\[View all \]](#)

- Feb 21, 2018 1:35 PM ET*
[RBC Capital Markets Global Healthcare Conference](#)
- Mar 13, 2017*
[Annual Report \(10-K\)](#)
- Jul 10, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 7, 2017*
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)